Chang Su1, Kevin A Nguyen2, Harrison X Bai3, Ya Cao4, Yongguang Tao4, Rong Xiao5, Giorgos Karakousis6, Paul J Zhang7, Guiying Zhang8. 1. Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; Yale School of Medicine, New Haven, Connecticut. 2. Department of Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, Connecticut. 3. Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, People's Republic of China. 5. Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. 6. Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 7. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 8. Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Electronic address: guiyingzhang2@gmail.com.
Abstract
BACKGROUND: Studies have shown contradictory results regarding the survival outcomes among white, African American, and Asian patients with mycosis fungoides (MF). OBJECTIVE: To evaluate the survival outcomes among white, African American, and Asian patients with MF and to determine other prognostic factors of the disease. METHODS: The US National Cancer Database was used to identify patients with histologically confirmed MF from 2004 to 2014. Clinicopathologic, socioeconomic, and treatment data were compared among the races by using the chi-square test. Overall survival was evaluated by using the log-rank test, multivariable Cox proportional hazard regression, and propensity score-matched analysis. RESULTS: Of 4459 patients with MF, 77.7% were white, 19.2% were African American, and 3.2% were Asian. Older age, treatment received in a community facility, government insurance, higher Charlson-Deyo score, male sex, higher clinical stage, receipt of radiotherapy or chemotherapy, and African American race were predictors of poor overall survival on multivariate analysis (P < .001), whereas Asian race trended toward improved outcomes (P = .07). LIMITATIONS: Retrospective analysis. CONCLUSION: African American patients with MF demonstrated poorer survival than white patients after accounting for disease characteristics, socioeconomic factors, and types of treatment, warranting further investigation into the underlying biology of MF and prescribed treatment modalities.
BACKGROUND: Studies have shown contradictory results regarding the survival outcomes among white, African American, and Asian patients with mycosis fungoides (MF). OBJECTIVE: To evaluate the survival outcomes among white, African American, and Asian patients with MF and to determine other prognostic factors of the disease. METHODS: The US National Cancer Database was used to identify patients with histologically confirmed MF from 2004 to 2014. Clinicopathologic, socioeconomic, and treatment data were compared among the races by using the chi-square test. Overall survival was evaluated by using the log-rank test, multivariable Cox proportional hazard regression, and propensity score-matched analysis. RESULTS: Of 4459 patients with MF, 77.7% were white, 19.2% were African American, and 3.2% were Asian. Older age, treatment received in a community facility, government insurance, higher Charlson-Deyo score, male sex, higher clinical stage, receipt of radiotherapy or chemotherapy, and African American race were predictors of poor overall survival on multivariate analysis (P < .001), whereas Asian race trended toward improved outcomes (P = .07). LIMITATIONS: Retrospective analysis. CONCLUSION: African American patients with MF demonstrated poorer survival than white patients after accounting for disease characteristics, socioeconomic factors, and types of treatment, warranting further investigation into the underlying biology of MF and prescribed treatment modalities.
Authors: Raghav Tripathi; Konrad D Knusel; Harib H Ezaldein; Jeffrey F Scott; Jeremy S Bordeaux Journal: JAMA Dermatol Date: 2018-11-01 Impact factor: 10.282
Authors: Pamela B Allen; Subir Goyal; Tim Niyogusaba; Colin O'Leary; Amy Ayers; Erica S Tarabadkar; Mohammad K Khan; Mary Jo Lechowicz Journal: JAMA Dermatol Date: 2022-09-07 Impact factor: 11.816
Authors: Shiun Chang; Lucia Seminario-Vidal; Kenneth Y Tsai; Pei-Ling Chen; Xiaofei Song; Alvaro de Mingo Pulido; Leticia Tordesillas; Xingzhi Song; Rhianna A Reed; Andrea Harkins; Shannen Whiddon; Jonathan V Nguyen; Carlos Moran Segura; Chaomei Zhang; Sean Yoder; Zena Sayegh; Yun Zhao; Jane L Messina; Carly M Harro; Xiaohui Zhang; José R Conejo-Garcia; Anders Berglund; Lubomir Sokol; Jianhua Zhang; Paulo C Rodriguez; James J Mulé; Andrew P Futreal Journal: Cancer Discov Date: 2022-05-02 Impact factor: 38.272
Authors: Shamir Geller; Emily Lebowitz; Melissa P Pulitzer; Steven M Horwitz; Alison J Moskowitz; Steve Dusza; Patricia L Myskowski Journal: J Am Acad Dermatol Date: 2019-09-06 Impact factor: 11.527
Authors: Xochiquetzal U Martinez; Arnab Chowdhury; Tracey Stiller; Joycelynne Palmer; Matthew Loscalzo; Estella Barrios; Farah R Abdulla; Jasmine Zain; Steven T Rosen; Christiane Querfeld Journal: Support Care Cancer Date: 2021-05-07 Impact factor: 3.603
Authors: Subuhi Kaul; Micah Belzberg; John-Douglas Matthew Hughes; Varun Mahadevan; Raveena Khanna; Pegah R Bakhshi; Michael S Hong; Kyle A Williams; Annie L Grossberg; Shawn G Kwatra; Ronald J Sweren Journal: Medicines (Basel) Date: 2019-12-26